Last Updated: April 29, 2026

CLINICAL TRIALS PROFILE FOR HMPL-689

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for HMPL-689

Subscribe to access the full database, or Start Trial
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02631642 ↗	A Study of HMPL-689 in Healthy Volunteers	Completed	Hutchison Medipharma Limited	Phase 1	The purpose of this study is to evaluate the safety and tolerability of a single dose of HMPL-689 in healthy volunteers To determine the pharmacokinetic profile of single oral doses of HMPL-689 in healthy volunteers
NCT03128164 ↗	A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed	Unknown status	Hutchison Medipharma Limited	Phase 1	This is a Phase 1, open-label study of HMPL-689 administered orally to patients with lymphoma for whom failed of standard care or have no standard of care.This study will consist of a dose escalation stage (Stage I) and a dose expansion stage (Stage II).
NCT03786926 ↗	Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas	Recruiting	Hutchison Medipharma Limited	Phase 1	An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas
NCT04849351 ↗	Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma	Recruiting	Hutchison Medipharma Limited	Phase 2	A Multi-center, Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of HMPL-689 in Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL)
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for HMPL-689

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Lymphomas	1
Marginal Zone Lymphoma	1
Relapsed/Refractory Lymphoma	1
Follicular Lymphoma	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Lymphoma	4
Lymphoma, Follicular	1
Lymphoma, B-Cell, Marginal Zone	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for HMPL-689

Trials by Country

Map
Table

Trials by Country
Location	Trials
China	24
United States	5
Australia	2
Italy	1
Spain	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
Florida	1
Texas	1
North Carolina	1
Georgia	1
Arkansas	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for HMPL-689

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 2	2
Phase 1	4
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Recruiting	2
Completed	2
Unknown status	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for HMPL-689

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Hutchison Medipharma Limited	4
Hutchmed	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	6
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.